You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(603259.SH)半年度淨利潤預增53%到55%
格隆匯 07-15 16:50

格隆匯7月15日丨藥明康德(603259.SH)公佈,預計2021年度實現歸屬於公司股東的淨利潤與上年同期的人民幣171715.54萬元相比增加人民幣91009.24萬元人民幣94443.55萬元同比53%55%

預計2021年度實現歸屬於公司股東的扣除非經常性損益的淨利潤與上年同期的人民幣113110.93萬元相比增加人民幣97275.4萬元到人民幣99537.62萬元,同比增長86%88%主要有如下兩個因素驅動:

1主營業務收入方面,公司延續一季度的強勁增長勢頭,在合同研發與生產(CDMO)等高景氣度業務的推動下,二季度銷售收入持續強勁增長。其中臨牀研究及其他CRO服務,由於國內新冠疫情導致的成本影響已基本去除,較可比期間呈現大幅增長。

2經營利潤方面,公司的經營效率仍保持在良好水平,去年同比期間由於新冠疫情導致的較低的運營效率已全面恢復,公司產能利用和經營效率得到不斷提升,經營利潤增長顯著。

公司2021年度非經常性損益項目的影響與上年同期相比有所增長,主要由於公司所投資的已上市公司標的及非上市公司股權的市場價值上漲原因,使公司部分非流動金融資產的公允價值變動收益以及投資收益增長較大,預計影響2021年度利潤金額人民幣204876.29萬元左右上年同期影響金為淨收益人民幣103115.89萬元。另一方面由於公司H可轉生金融工具部分的公允價值受公司H股價大幅上漲影響,2021半年現金賬面公允價值損失金額預計為人民幣149333.98萬元左右,上年同期為淨損失人民幣48679.90萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account